3 Psychedelic Sector Leaders That Investors Need To Be Aware OfPsyched Wellness Announces New OTCQB Ticker: PSYCF2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private Placement

Who Will Be The First To Get A Psychedelic Drug Through The FDA To Commercialization?

Nov 25, 2020 • 7:54 AM EST
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

In 2016, GW Pharmaceuticals plc (GWPH) put the medical cannabis industry on the map when it reported positive data from a US Food and Drug Administration (FDA) Phase 3 clinical trial. The Phase 3 clinical trial was on Dravets Syndrome (which is a serious form of epilepsy) and the market rewarded GW with a much higher stock price as a result of the positive data.

Fast forward to 2020 and GW is valued at more than $4 billion by its market capitalization (as of November 25th) and generates more than $100 million of revenue per quarter. The advancement of the Nasdaq traded biotech cannabis company over the last decade has been impressive and many analysts are trying to determine which company will be the GW of the psychedelic therapy industry.

Currently, there are three psychedelic therapy companies that are conducting Phase 3 FDA clinical trials. In 2021, we expect these companies to announce results from these studies and believe that at least one of the firms will report positive data. The companies that are some of the first to reach this milestone will most likely follow a path that is similar to GW.

One of the reasons we are favorable on the potential for a company to be the GW of the psychedelic therapy industry is related to the impact it will have on the capital raising process. After GW reported positive Phase 3 data, there was a large increase in the average size of its capital raises. Also, the amount of interest in the financings increased exponentially and GW had no issue at raising capital for additional therapies in its clinical trial pipeline.

When it comes to the psychedelic therapy market, we are focused on companies that are developing treatments that have a large total addressable market. We also prefer companies that have put a major emphasis on the development of an intellectual property (IP) portfolio and on the importance of human capital.

For companies that are in the pre-clinical and/or clinical trial process, the market cares less about quarterly financial results and more about data that supports the study. For these early-stage companies, positive clinical trial data can prove to be a gamechanger on the capital markets side of the business. Due to this, we tend to prefer companies that own valuable IP and are led by a team that has previously brought therapies through the FDA clinical trial process and to market.

We believe that 2021 will be a banner year for the psychedelic therapy market and are focused on a handful of companies that are executing on a strategy to become the GW of the sector. If you are interested in learning more about these companies, please send an email to support@mushroomstocks.com with the subject “Psychedelic Therapy Companies” to be added to our distribution list.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.